Literature DB >> 11123065

Antiphospholipid antibodies and platelets.

A De Jong1, V Ziboh, D Robbins.   

Abstract

The most distinguishing serologic feature of antiphospholipid syndrome (APS) is the moderate to high blood titers of antiphospholipid-binding antibodies (aPL). The pathogenic mechanisms of APS are poorly understood, but may occur as a result of the interaction between anticardiolipin antibodies (aCL), beta-2 glycoprotein-I (beta(2)GP-I) (the aCL cofactor) and blood platelets. However, the relationship between aCL/beta(2)GP-I complexes and platelet aggregation has yet to be clearly elucidated. This article will briefly review aPL, beta(2)GP-I and platelet physiology with respect to recent hypotheses relating aCL/beta(2)GP-I complexes and platelets.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11123065     DOI： 10.1007/s11926-000-0085-8

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


  38 in total

1.  Molecular basis of the apolipoprotein H (beta 2-glycoprotein I) protein polymorphism.

Authors:  D K Sanghera; T Kristensen; R F Hamman; M I Kamboh
Journal:  Hum Genet       Date:  1997-07       Impact factor: 4.132

2.  Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.

Authors:  M Galli; P Comfurius; C Maassen; H C Hemker; M H de Baets; P J van Breda-Vriesman; T Barbui; R F Zwaal; E M Bevers
Journal:  Lancet       Date:  1990-06-30       Impact factor: 79.321

Review 3.  Transbilayer movement of phospholipids in red cell and platelet membranes.

Authors:  A J Schroit; R F Zwaal
Journal:  Biochim Biophys Acta       Date:  1991-11-13

4.  Platelet activation in patients with antiphospholipid syndrome.

Authors:  Y Shechter; Y Tal; A Greenberg; B Brenner
Journal:  Blood Coagul Fibrinolysis       Date:  1998-10       Impact factor: 1.276

Review 5.  Pathogenic role of antiprotein-phospholipid antibodies.

Authors:  L O Carreras; R R Forastiero
Journal:  Haemostasis       Date:  1996-10

6.  Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor.

Authors:  E Matsuura; Y Igarashi; M Fujimoto; K Ichikawa; T Suzuki; T Sumida; T Yasuda; T Koike
Journal:  J Immunol       Date:  1992-06-15       Impact factor: 5.422

7.  Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I.

Authors:  J Nimpf; E M Bevers; P H Bomans; U Till; H Wurm; G M Kostner; R F Zwaal
Journal:  Biochim Biophys Acta       Date:  1986-10-29

8.  Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibody.

Authors:  E N Harris; R A Asherson; A E Gharavi; S H Morgan; G Derue; G R Hughes
Journal:  Br J Haematol       Date:  1985-02       Impact factor: 6.998

9.  Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986.

Authors:  E N Harris; A E Gharavi; S P Patel; G R Hughes
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

10.  Demonstration of antiphospholipid antibody heterogeneity by phospholipid column chromatography and salt gradient elution techniques.

Authors:  S P Walton; S S Pierangeli; A Campbell; E Klein; B Burchitt; E N Harris
Journal:  Lupus       Date:  1995-08       Impact factor: 2.911
View more
  4 in total

Review 1.  Complement activation on platelets: implications for vascular inflammation and thrombosis.

Authors:  Ellinor I Peerschke; Wei Yin; Berhane Ghebrehiwet
Journal:  Mol Immunol       Date:  2010-06-01       Impact factor: 4.407

2.  Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies.

Authors:  E I B Peerschke; W Yin; D R Alpert; R A S Roubey; J E Salmon; B Ghebrehiwet
Journal:  Lupus       Date:  2009-05       Impact factor: 2.911

3.  Platelet distribution width is highly associated with thrombotic events in primary antiphospholipid syndrome.

Authors:  Yu Shi; Hui Jiang; Can Huang; Chaojun Hu; Jiuliang Zhao; Mengtao Li; Xiaofeng Zeng
Journal:  Clin Rheumatol       Date:  2021-07-02       Impact factor: 2.980

Review 4.  The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS.

Authors:  Thomas McDonnell; Chris Wincup; Ina Buchholz; Charis Pericleous; Ian Giles; Vera Ripoll; Hannah Cohen; Mihaela Delcea; Anisur Rahman
Journal:  Blood Rev       Date:  2019-08-16       Impact factor: 10.626
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.